FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
about
FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapiesConserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancerFAM83B mediates EGFR- and RAS-driven oncogenic transformationHyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83BProtein associated with SMAD1 (PAWS1/FAM83G) is a substrate for type I bone morphogenetic protein receptors and modulates bone morphogenetic protein signallingSignaling cross-talk in the resistance to HER family receptor targeted therapyFAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistancePopulation effect model identifies gene expression predictors of survival outcomes in lung adenocarcinoma for both Caucasian and Asian patients.HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss.Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancerCharacterization of the human cumulus cell transcriptome during final follicular maturation and ovulation.Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidencePharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft miceMicroarray expression profiling identifies genes, including cytokines, and biofunctions, as diapedesis, associated with a brain metastasis from a papillary thyroid carcinoma.Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.miR-143 inhibits tumor progression by targeting FAM83F in esophageal squamous cell carcinoma.Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Pathways Involved in Formation of Mammary Organoid Architecture Have Keys to Understanding Drug Resistance and to Discovery of Druggable Targets.FAM83 family oncogenes are broadly involved in human cancers: an integrative multi-omics approachFAM83A and FAM83B: candidate oncogenes and TKI resistance mediators.FAM83A is amplified and promotes cancer stem cell-like traits and chemoresistance in pancreatic cancerdecodeRNA- predicting non-coding RNA functions using guilt-by-association.Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics.Laminin signals initiate the reciprocal loop that informs breast-specific gene expression and homeostasis by activating NO, p53 and microRNAs.The FAM83 family of proteins: from pseudo-PLDs to anchors for CK1 isoforms.The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms.Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer.
P2860
Q24292888-376EC57F-CD7C-46BB-A4D6-71A15C699D57Q24294761-93B8F5AC-5FA9-491C-AE75-86E567F45FFCQ24296283-BC498B62-13F0-4DD2-A04C-77BC0F17F204Q24314709-263DBBB6-F57D-4C8D-B090-4AF7CD8346E9Q24337871-D356FE81-AE93-4D2D-9DAA-59BC5BCF38D4Q27027778-7F1CE87F-8C7F-488F-A0C9-F80E6B0CE8D3Q28077347-5290C1C3-1D40-4E22-92AD-C44F29B51FD4Q33584831-ADF54BD6-0A71-40D8-B1C2-02C7AA93A2E7Q33626569-DB6BFE96-87A4-4E56-A6D3-7A55936AD2D4Q33827681-E79997B1-A857-400B-8E86-641FCEA1EAA9Q34291977-DE37970F-74FB-423C-BBD9-F1657F90AE04Q35158295-0D35958C-C530-4A7B-B265-FD7DE3EDAAD6Q35633666-08B8CA42-E641-4143-890E-F127BF47CD96Q36250585-0CC8E448-F528-465F-ACB8-1E0D6D5EE7FFQ37112320-96FF4731-DCAE-4BDA-85ED-2AC8EE9833C8Q37382508-F27742EE-2AE5-4FB4-AD15-F5B303E0A516Q38718320-A9BEE8E3-C2D2-4E09-B49C-E18477658F5EQ38804349-36D13342-FC42-48E1-8F40-04490736703DQ38812867-0BA57954-3BAE-4B49-8934-B2980ECF2837Q39247023-5AD546AA-EF2E-4300-B79E-093859CAF5FCQ41127852-AB6B5B48-5237-4F5D-B157-F81352D93BD6Q42059865-1E1EF698-C627-40E9-92AB-3FE54FAEF48BQ42339289-436487EF-5574-45DE-AE4C-C969433531ABQ47139299-D471C93D-AB00-43A2-957F-29C009BCBF1DQ49167162-4B9EA0B6-99A8-47E4-BBAA-B74903F5CE8FQ52725291-B2FF6306-D208-452A-8533-9100E31B8308Q54976961-2DE20D9D-DBC7-4B1C-B012-31B686E2AA94Q54978506-06AB7852-A105-42F5-92AE-FF6C13634E8DQ55058467-4F7010CE-8C4E-41E2-8136-D8831BD16B2F
P2860
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
@ast
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
@en
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
@en-gb
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
@nl
type
label
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
@ast
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
@en
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
@en-gb
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
@nl
prefLabel
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
@ast
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
@en
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
@en-gb
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
@nl
P2093
P2860
P3181
P356
P1476
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
@en
P2093
Marc E Lenburg
Mina J Bissell
Paraic A Kenny
Roland Meier
Sun-Young Lee
P2860
P304
P3181
P356
10.1172/JCI60498
P407
P577
2012-08-13T00:00:00Z